Since the emergence of methicillin-resistant Staphylococcus aureus 60 years ago, scientists have been trying to engineer β-lactam antibiotics to restore drug susceptibility. Genomic data now shows that clavulanic acid (a β-lactamase inhibitor) can restore susceptibility in many strains, but only if they carry key mutations.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Kourtis, A. P. et al. MMWR-Morbid. Mortal. W. 68, 214–219 (2019).
Harrison, E. M. et al. Nat. Microbiol. https://doi.org/10.1038/s41564-019-0471-0 (2019).
Cantoni, L., Wenger, A., Glauser, M. P. & Bille, J. J. Infect. Dis. 159, 989–993 (1989).
Nicolas, M. H., Kitzis, M. D. & Karim, A. Med. Maladies Infect. 23, 82–94 (1993).
Andreoni, M., Raillard, P., Concia, E. & Wang, Y. Curr. Ther. Res. Clin. E. 50, 386–395 (1991).
Chambers, H. F., Sachdeva, M. & Kennedy, S. J. Infect. Dis. 162, 705–710 (1990).
Chambers, H. F., Kartalija, M. & Sande, M. J. Infect. Dis. 171, 897–902 (1995).
About this article
Cite this article
Hamilton, F., MacGowan, A. A long history of β-lactams for MRSA. Nat Microbiol 4, 1604–1605 (2019). https://doi.org/10.1038/s41564-019-0561-z